Publications
2024
Montani C., Galbusera A., D'Epifanio B., Ghirardini E., Cornuti S., Pasquin Mariani J.R., De Guzman E., Mandrup Bertozzi S., Armirotti A., Baroncelli L., Gozzi A.
Connectomic and behavioral alterations in creatine transporter deficiency are partially normalized by gene therapy
Biorxiv
2024
Brindani N., Vuong L.M., La Serra M.A., Salvador N., Menichetti A., Acquistapace I.M., Ortega J.A., Veronesi M., Bertozzi S.M., Summa M., Girotto S., Bertorelli R., Armirotti A., Ganesan A.K., De Vivo M.
Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy
Journal of Medicinal Chemistry, vol. 67, (no. 12), pp. 10401-10424
2024
Ciobanu D.Z., Liessi N., Tomati V., Capurro V., Bertozzi S.M., Summa M., Bertorelli R., Loberto N., Dobi D., Aureli M., Nobbio L., Bandiera T., Pedemonte N., Bassi R., Armirotti A.
Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)
Journal of Cystic Fibrosis
2023
Brindani N., Vuong L.M., Acquistapace I.M., La Serra M.A., Ortega J.A., Veronesi M., Bertozzi S.M., Summa M., Girotto S., Bertorelli R., Armirotti A., Ganesan A.K., De Vivo M.
Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer
Journal of Medicinal Chemistry, vol. 66, (no. 8), pp. 5981-6001
2023
Basagni F., Ortega J.A., Bertozzi S.M., Armirotti A., Summa M., Bertorelli R., Bartolini M., Mellor I.R., Bedeschi M., Bottegoni G., Lembo V., Minarini A., Cavalli A., Rosini M.
Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties
European Journal of Medicinal Chemistry, vol. 261
2023
Bellina F., Berti F., Bertozzi S. M., Bandiera T., Bertozzi F.
Highly diastereoselective Heck-Matsuda reaction with pyrazolyl diazonium salts
New Journal of Chemistry
Article in Press
Journal
2023
Scarpelli R., Palomba M., Vecchio D., Ottonello G., Mandrup Bertozzi S., Summa M., Armirotti A., Bertorelli R., De Mei C., Grimaldi B.
Identification of a dual REV-ERBβ and autophagy inhibitor with in vivo anticancer efficacy (P222)- September 3-7, 2023, Zagreb (Croatia)
IX EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry
Poster
Conference
2023
Stuefer A., Balasco L., Gini S., Coletta L., Rocchi F., Montani C., Alvino F.G., Sastre D., Galbusera A., Aldrighetti M., Mandrup Bertozzi S., Lau Poui Cheung P., Vozzi D., Papaleo F., Iurilli G., Armirotti A., Cancedda L., Lombardo M., Bozzi Y., Gozzi A.
Transient neocortical excitatory / inhibitory imbalance during early infancy leads to permanent social impairments
Neurobiology of social behaviors
Poster
Conference
2022
Tuccinardi D., Di Mauro A., Lattanzi G., Rossini G., Monte L., Beato I., Spiezia C., Bravo M., Watanabe M., Soare A., Kyanvash S., Armirotti A., Bertozzi S.M., Gastaldelli A., Pedone C., Khazrai Y.M., Pozzilli P., Manfrini S.
An extra virgin olive oil-enriched chocolate spread positively modulates insulin-resistance markers compared with a palm oil-enriched one in healthy young adults: A double-blind, cross-over, randomised controlled trial
Diabetes/Metabolism Research and Reviews, vol. 38, (no. 2)
2022
Jahid S., Ortega J.A., Vuong L.M., Acquistapace I.M., Hachey S.J., Flesher J.L., La Serra M.A., Brindani N., La Sala G., Manigrasso J., Arencibia J.M., Bertozzi S.M., Summa M., Bertorelli R., Armirotti A., Jin R., Liu Z., Chen C.-F., Edwards R., Hughes C.C.W., De Vivo M., Ganesan A.K.
Erratum: Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer (Cell Reports (2022) 39(1), (S221112472200393X), (10.1016/j.celrep.2022.110641))
Cell Reports, vol. 39, (no. 4)
2022
Colini Baldeschi A., Zattoni M., Vanni S., Nikolic L., Ferracin C., La Sala G., Summa M., Bertorelli R., Bertozzi S.M., Giachin G., Carloni P., Bolognesi M.L., De Vivo M., Legname G.
Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance
Journal of Medicinal Chemistry, vol. 65, (no. 13), pp. 8998-9010
2022
Jahid S., Ortega J. A., Vuong L. M., Hachey S. J., Flesher J. L., La Serra M. A., Brindani N., La Sala G., Manigrasso J., Arencibia J. M., Bertozzi S. M., Summa M., Bertorelli R., Armirotti A., Chen C., Hughes C. C. W., Edwards R., De Vivo M., Ganesan A. K.
Structure-based Design of CDC42 Effector Interaction Inhibitors For the Treatment of Cancer
Cell Reports, vol. 39, pp. 110641
2021
Borgogno M., Savardi A., Manigrasso J., Turci A., Portioli C., Ottonello G., Bertozzi S.M., Armirotti A., Contestabile A., Cancedda L., De Vivo M.
Design, Synthesis,In VitroandIn VivoCharacterization of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in down Syndrome
Journal of Medicinal Chemistry, vol. 64, (no. 14), pp. 10203-10229
2021
Di Fruscia P., Carbone A., Bottegoni G., Berti F., Giacomina F., Ponzano S., Pagliuca C., Fiasella A., Pizzirani D., Ortega J.-A., Nuzzi A., Tarozzo G., Mengatto L., Giampà R., Penna I., Russo D., Romeo E., Summa M., Bertorelli R., Armirotti A., Bertozzi S.M., Reggiani A., Bandiera T., Bertozzi F.
Discovery and SAR evolution of pyrazole azabicyclo[3.2.1]octane sulfonamides as a novel class of non-covalent N-Acylethanolamine-hydrolysing Acid Amidase (NAAA) inhibitors for oral administration
Journal Medicinal Chemistry
2021
Capurro V., Tomati V., Sondo E., Renda M., Borrelli A., Pastorino C., Guidone D., Venturini A., Giraudo A., Bertozzi S.M., Musante I., Bertozzi F., Bandiera T., Zara F., Galietta L.J.V., Pedemonte N.
Partial rescue of f508del-cftr stability and trafficking defects by double corrector treatment
International Journal of Molecular Sciences, vol. 22, (no. 10)